3459 |
[Case #3: TAVR in a Patient of Failing Aoritc Prosthetic Valve with AR and Paravalvular Leak] Part 2. How Would I Treat? |
Paul Toon Lim Chiam |
Apr. 28. 18 |
3458 |
Expanding Role of NOAC in PCI/AF, ACS, and Stable ASCVD: Recent Trials and Next Expectations |
David Joel Cohen |
Apr. 28. 18 |
3457 |
[Case #3: TAVR in a Patient of Failing Aoritc Prosthetic Valve with AR and Paravalvular Leak] Part 1. How Should I Treat? |
Tien-Ping Tsao |
Apr. 28. 18 |
3456 |
Why DAPT Trial Not Followed?: Moving Forward Less Duration with Smart DES, De-Escalating Strategy, and P2Y12 Inhibitor Monotherapy |
Dominick J. Angiolillo |
Apr. 28. 18 |
3455 |
[Case #2: Transcatheter Aortic Valve Implantation in a Patient with Type B Aortic Dissection] Part 3. How Did I Treat? |
Hsin-Bang Leu |
Apr. 28. 18 |
3454 |
Rapid Changing TAVR Story: Predicting the Future from Ongoing TAVR Clinical Trials |
Eberhard Grube |
Apr. 28. 18 |
3453 |
[Case #2: Transcatheter Aortic Valve Implantation in a Patient with Type B Aortic Dissection] Part 2. How Would I Treat? |
Jung-Min Ahn |
Apr. 28. 18 |
3452 |
Contemporary and Future Metallic DES: What Do We Expect More from Ongoing PCI Trials? |
Alan C. Yeung |
Apr. 28. 18 |
3451 |
ABSORB III, IV, Updated Meta, and More - Expert Future Expectation on Bioabsorbable Scaffolds |
Gregg W. Stone |
Apr. 28. 18 |
3450 |
WATCHMAN: Data Synthesis and Ongoing Trials |
David R. Holmes |
Apr. 28. 18 |